Table 3.

Risk Factors Impacting Survival

	β	S.E.	z	P
(Intercept)	3.491	0.093	37.171	<0.001
Dose	0.001	<0.001	9.593	<0.001
Dexrazoxane	−0.019	0.034	−0.545	0.586
Topoisomerase Inhibitor	−0.967	0.009	−104.086	<0.001
Antimetabolite	0.234	0.035	6.599	<0.001
Female (%)	−6.095	0.209	−29.106	<0.001

Cumulative dose of anthracyclines and simultaneous chemotherapy with antimetabolite agents significantly and positively increased survival rates. Use of topoisomerase inhibitors and female gender significantly decreased survival rates. Use of cardioprotectant agents (I.e. dexrazoxane) had no effect on overall survival rates.